Troluce Capital Advisors LLC Takes Position in Immatics N.V. $IMTX

Troluce Capital Advisors LLC bought a new position in shares of Immatics N.V. (NASDAQ:IMTX) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 250,000 shares of the company’s stock, valued at approximately $2,460,000.

A number of other large investors also recently modified their holdings of IMTX. Vanguard Personalized Indexing Management LLC grew its position in Immatics by 3.7% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 49,374 shares of the company’s stock valued at $518,000 after purchasing an additional 1,739 shares during the period. Bank of America Corp DE increased its stake in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after purchasing an additional 2,231 shares in the last quarter. Barclays PLC raised its holdings in Immatics by 11.4% during the fourth quarter. Barclays PLC now owns 28,185 shares of the company’s stock worth $296,000 after buying an additional 2,874 shares during the last quarter. Virtus Investment Advisers LLC raised its holdings in Immatics by 43.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company’s stock worth $278,000 after buying an additional 7,965 shares during the last quarter. Finally, Quarry LP acquired a new position in Immatics during the fourth quarter worth $84,000. 64.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IMTX has been the subject of a number of analyst reports. TD Cowen initiated coverage on shares of Immatics in a report on Tuesday, April 28th. They set a “buy” rating for the company. Wall Street Zen lowered shares of Immatics from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. Weiss Ratings cut shares of Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Immatics in a research report on Tuesday, May 19th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

Immatics Stock Performance

Shares of Immatics stock opened at $9.08 on Monday. The company has a market capitalization of $1.22 billion, a P/E ratio of -4.56 and a beta of 1.32. The stock has a fifty day simple moving average of $9.97 and a 200 day simple moving average of $10.11. Immatics N.V. has a 12-month low of $5.05 and a 12-month high of $12.41.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.08). The company had revenue of $8.81 million for the quarter, compared to the consensus estimate of $9.79 million. Immatics had a negative net margin of 572.35% and a negative return on equity of 47.36%. On average, analysts predict that Immatics N.V. will post -1.67 EPS for the current year.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.